Joint Development and Distribution Agreement with Fuji Pharma ~ Collaboration of Capabilities for End-to-end Solutions ~Joint Development and Distribution Agreement • November 12th, 2020
Contract Type FiledNovember 12th, 2020M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL: https://corporate.m3.com/; “M3,” below) and Fuji Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President & CEO: Takayuki Iwai; URL: https://www.fujipharma.jp/; “Fuji Pharma” below), has announced an agreement for joint development and distribution of a Estetrol/Drospirenone combination product (“the product,” below), to establish a digitally optimized distribution structure upon its approval for manufacturing and distribution.